key: cord-0260054-s77yprca
authors: Lambert, B.; Stopard, I.; Momeni-Boroujeni, A.; Mendoza, R.; Zuretti, A.
title: Using patient biomarker time series to determine mortality risk in hospitalised COVID-19 patients: a comparative analysis across two New York hospitals
date: 2021-12-08
journal: nan
DOI: 10.1101/2021.11.12.21266248
sha: ed4a80b0433379e0bb8452c393278cc65c39965b
doc_id: 260054
cord_uid: s77yprca

A large range of prognostic models for determining the risk of COVID-19 patient mortality exist, but these typically restrict the set of biomarkers considered to measurements available at patient admission. Additionally, many of these models are trained and tested on patient cohorts from a single hospital, raising questions about the generalisability of results. We used a Bayesian Markov model to analyse time series data of biomarker measurements taken throughout the duration of a COVID-19 patient's hospitalisation for n=1540 patients from two hospitals in New York: State University of New York (SUNY) Downstate Health Sciences University and Maimonides Medical Center. In doing so, we quantified the mortality risk associated with both static (e.g. demographic and patient history variables) and dynamic factors (e.g. changes in biomarkers) throughout hospitalisation. By using our model to make predictions across the hospitals, we assessed how predictive factors generalised between the two cohorts. The individual dynamics of the measurements and their associated mortality risk were remarkably consistent across the hospitals. The model accuracy in predicting patient outcome (death or discharge) was 72.3% (predicting SUNY; posterior median accuracy) and 71.4% (predicting Maimonides) respectively. Model sensitivity was higher for detecting patients who would go on to be discharged (79.2%) versus those who died (61.0%). Our results indicate the utility of including dynamic clinical measurements when assessing patient mortality risk but also highlight the difficulty of identifying high risk patients.

Introduction 1 0.77) when internally and externally validated on a dataset of 66,705 patients [10] . 23 Similarly, peripheral oxygen saturation, urea level and C-reactive protein at 24 presentation are used to predict patient mortality [11] . Patients are, however, admitted 25 to hospital at different states of disease progression, and their biomarkers change 26 throughout the course of hospitalisation [12] [13] [14] [15] . Emerging evidence indicates a number 27 of time-dependent biomarkers changes may therefore be useful prognostic factors: 28 increases in platelets and eosinophil percentage are indicative of reduced mortality risk, 29 whilst increases in alkaline phosphatase may indicate increased mortality risk [15] . 30 Incorporating dynamic changes in biomarkers can improve the predictive accuracy of 31 prognostic models when internally validated [14, 15] , but the external validation of these 32 prognostic factors is still required. The role of time-dependent biomarkers in different 33 patients remains a key question [16] . We previously developed a prognostic Markov 34 model, which allows the quantification of daily mortality risk and the impact of 35 dynamic changes in biomarkers on this quantity and fit the model to data from State 36 University of New York (SUNY) Downstate Medical Center [15] . In this study, we fit 37 the model to new data from a different New York hospital: Maimonides Medical Center 38 (henceforth "Maimonides"). We then compare the impact of dynamic changes in patient 39 biomarkers on in-hospital mortality risk (i.e. patient outcomes), across SUNY and 40 Maimonides. In doing so, we obtain an external validation of the model and, more 41 generally, allows us to appraise the use of dynamic biomarker measurements for 42 determining patient mortality risk. COVID-19-related symptoms, which was subsequently confirmed by RT PCR, from the 52 beginning of February 2020 until the end of May 2020. Stratified randomization was used to select at least 500 patients who were discharged and 500 patients who died due 54 to the complications of COVID-19. Patient outcome was recorded as a binary choice of 55 "discharged" versus "COVID-19 related mortality". Patients whose outcome was 56 unknown were excluded. Demographic, clinical history and laboratory data was 57 extracted from the hospital's electronic health records. The raw data were cleaned and 58 processed for analysis as described in §S1. 2 

where j indicates the binary variable (for example, whether an individual was aged 0-40 73 or whether they had a history of asthma); X j 0 and X j 1 indicate the counts of individuals 74 dying for the j = 0 and j = 1 subgroups; N j 0 and N j 1 are the observed counts of 75 individuals in the j = 0 and j = 1 subgroups; and θ j 0 and θ j 1 are the estimated 76 proportions dying in the corresponding subgroups. Parameters were estimated using a 77 Bayesian framework: the estimated ratio of θ j 1 /θ j 0 defined the OR for variable j and was 78 estimated by taking 100,000 independent draws from the posterior distributions of each 79 of θ j 1 and θ j 0 , assuming uniform priors. . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted December 8, 2021. ; https://doi.org/10.1101/2021.11.12.21266248 doi: medRxiv preprint the time taken for the outcome to occur, or allow dynamic variables to be included. A 98 patient's underlying risk of death may, however, change throughout the course of their 99 hospitalisation, which can be indicated by changes in certain biomarkers [15] . 100 Here, we briefly describe a multivariate discrete time Markov model which aims to 101 identify the importance of different prognostic factors on COVID-19 mortality risk and 102 estimate the change in individual patients' mortality risk throughout the course of 103 hospitalisation. (The model has previously been described more fully here: [15] .) The 104 model specifically accounts for the competing risks of discharge and death. Note, it is 105 possible to use cause-specific hazards models (Cox regressions for each event of interest, 106 treating the other event as censored) to estimate the cumulative incidence function but, 107 in these models, it is not possible to assess the impact of individual covariates on the 108 cumulative incidence function [18, 19] . By considering the sequence of outcomes for each 109 day each patient was in hospital, Markov models can simultaneously account for the risk 110 of discharge versus mortality: on the first day, patients are admitted and begin in the 111 "hospital" state; at the end of the first day, they either remain in hospital or transition 112 to the "discharged" or "death" states. On subsequent days, patients that remained in 

where i indicates a given patient; t indicates the day of hospital stay post-admission for 120 a given patient; α 1 and β 1 are vectors of regression coefficients relating to the vector of 121 (potentially time-varying) regressors in x it ; α 0i and β 0i are patient-specific intercepts.

The normalised probabilities of transitions between the states are then given by the 123 ratio of the un-normalised probabilities to the sum of all these:

; so that, for example, p discharged For two hypothetical patients, we illustrate how the probability of their observed trajectory is calculated. Note that p it refers to the probability of an observed transition, which is a function of the patient (i) and day (t): the time-dependence of probabilities is realised through eq. (2) and is due to (potential) changes in covariates.

Using this model, we performed five separate regressions, each with different groups 126 of independent variables (i.e. different x it in eq. (2)). In the first of these, we included 127

. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted December 8, 2021. ; https://doi.org/10.1101/2021.11.12.21266248 doi: medRxiv preprint only a single variable in an analysis to examine the influence of each variable in 128 isolation. The second regression included patient demographic characteristics ("patient" 129 variables), including their age, sex and ethnicity, and the day they were admitted to Table S1 .

The model was estimated in a Bayesian framework using the Stan's NUTS 142 sampler [20, 21] . We used priors for the regression coefficients that induce sparsity: 143 meaning that only the most predictive covariates would be estimated to have non-zero 144 effects. The priors for the parameters are shown in Table S2 . The univariate models To check that the Markov model provided a reasonable fit of the underlying data, we 151 performed a series of posterior predictive checks (see, for example, [22, 23] ). For the is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted December 8, 2021. ; https://doi.org/10.1101/2021.11.12.21266248 doi: medRxiv preprint estimates: ρ = 0.82, t 19 = 6.33, p < 0.01; here and throughout, ρ indicates Pearson 191 correlation coefficient estimates) (Fig 2A) . In Maimonides, the variables tended to be 192 less associated with risk than for SUNY (regression slope of posterior median estimates 193 for Maimonides on those from SUNY:β = 0.65, t 19 = 3.48, p < 0.01 against H 0 : β = 1). 194 Similarly, there was a significant positive correlation between the OR estimates of the 195 laboratory values at admission between the two hospitals 196 (ρ = 0.85, t 17 = 6.77, p < 0.01), and the regression slope was not significantly different 197 from 1 (t 17 = 0.22, p > 0.05) indicating there was no systematic differences in ORs 198 between hospitals for these variables (Fig 2B) . To compare the average dynamics of laboratory test values for patients throughout 205 the course of their hospitalisation, we also estimated hospital-specific time trends for 206 each patient group (see Methods). Across the majority of variables, there was a high 207 degree of correspondence in these average trends across the two hospitals (Fig 3) . . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted December 8, 2021. In what follows, we compare the the univariate ORs associated with daily mortality risk 216 for each of the common biomarkers across the two hospitals as derived from the Markov 217 model (described in Methods). There was a strong positive correlation 218 (ρ = 0.85, t 17 = 6.52, p < 0.01) in the estimates of the ORs between the hospitals (Fig 4) . 219 For 16/19 of the variables, the ORs estimates agreed in their "sign": 9/19 of the 220 variables had an OR > 1 (posterior medians) in both analyses; 7/19 had an OR < 1 in 221 both analyses. For the remaining variables, the ORs from Maimonides tended to be 222 lower than those of SUNY.

Based on these estimates, increases in MCV, decreases in LYM PCT, and decreases 224 in CO 2 throughout a patient's stay were associated with the strongest increase in 225 mortality risk. . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted December 8, 2021. ; https://doi.org/10.1101/2021.11.12.21266248 doi: medRxiv preprint regressors (the "post-admission" set described in Methods): in doing so, we aim to 228 isolate those factors which convey the most independent predictive power. In Fig S7A, 229 we correlate the ORs associated with the dynamic biomarker measurements across both 230 hospitals. In contrast to the univariate estimates, the relationship between the estimates 231 was less clear and the correlation in estimates was insignificant 232 (ρ = 0.06, t 17 = 0.23, p > 0.05). This result was, however, largely driven by the 233 estimates for MCHC and MCV which were very different across the hospitals; when the 234 estimates were replotted with these removed (Fig S7B) , the estimates appeared Across the different regressor sets, predictive accuracy was consistent across the 239 hospitals ( Fig 5A) . In all cases, the posterior median predictive accuracy using data 240 from Maimonides resulted in slightly higher prediction than when using data from 241 SUNY: likely due to the higher sample size for Maimonides. The results also show the 242 predictive power of dynamic laboratory measurements (included in the "post-admission" 243 set), which resulted in a substantial boost in accuracy across both hospitals over a 244 model including only those available at admission ("admission"). 245 We next used the model using all available post-admission variables to probe its 246 predictive performance for those groups patients who went on to be discharged and died. 247 To do so, we pooled predictions across both independent hospital testing sets. The 248 resultant confusion matrix is shown in Fig 5B. This indicates that the model had a 249 higher sensitivity to determine patients that would eventually be discharged (posterior 250 mean: 79.2%) compared to those who would go on to die (61.0%). 251 We next assessed the reduction in accuracy when predicting patient outcomes in the 252 same hospital versus a different hospital. We did this by using validation sets either 253 comprised of separate data from the same hospital ("within') or a different hospital 254 November 12, 2021 9/14 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted December 8, 2021. ;

("between"). In Fig S8, we show the predictive accuracy for models fitted using data 255 from SUNY (left panel) and Maimonides (right panel). Point colour indicates whether 256 the validation set comprised patients from within the same hospital (green) or a different 257 hospital (orange). Note that, in this analysis, the requirement for an independent 258 within-hospital datasets to fit the model meant that the training datasets were smaller 259 than those used to produce Fig 5A: resulting in slightly lower overall accuracy. In 260 almost all cases, median predicted accuracy when predicting outcomes within the same 261 hospital was higher than that when predicting those in a different hospital. The 262 difference, however, was relatively small (mean difference in posterior medians: 2.1%), 263 indicating that the predictions generalised well from one location to another. Predictive accuracy in patient outcomes for held-out hospital. Panel A shows the accuracy in predicting outcomes across four regression sets: Colours indicate the hospital whose data was used to train the model: so, for example, "SUNY" indicates that data from this hospital was used to fit the model which was then tested on Maimonides. The horizontal axis shows the accuracy in predicting patient outcomes (i.e. death or discharge) using a Markov regression model with covariate sets as named on the vertical axis. The points and whiskers indicate the posterior medians and 2.5%-97.5% posterior intervals for the percentage of patients whose outcome was correctly determined across posterior draws. Panel B shows a confusion matrix for between-hospital prediction using Markov model with the post-admission covariate set.

Here, the values show the mean percentage of each outcome type correctly predicted across all posterior samples.

To determine whether there were subgroups of patients where the model performed 265 better or worse, we examined the factors that influenced the predictive accuracy for 266 those patients who went on to die in each of the hospitals. To do so, we used the models 267 that were trained on all the data from one hospital (i.e. those used to produce Fig 5A) . 268 We then used a random forest to predict posterior median predictive accuracy for each 269 of the patients, as a function of their time-invariant characteristics. Then using the 270 "impurity" measure of variable importance, we identified those variables that were 271 associated with differences in predictive accuracy. The top three factors were: the time 272 since the first patient was admitted to that hospital with COVID-19, whether the 273 patient had a history of coronary artery disease and whether their self-reported 274 ethnicity was categorised as non-Caucasian. These three variables were then included in 275 a linear regression to predict median predictive accuracy. This regression indicated that 276 having a history of coronary artery disease led to improved predictive power 277 (β = 0.14, t 478 = 6.52, p < 0.01); other factors were insignificant.

November 12, 2021 10/14 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted December 8, 2021. ; https://doi.org/10.1101/2021.11.12.21266248 doi: medRxiv preprint

A number of studies have demonstrated that dynamic changes in certain laboratory tests 280 may have potential as COVID-19 prognostic factors [12, 14, 15] . Here, we demonstrate 281 the external validation of a number of these dynamic biomarkers. In accordance with 282 existing studies, we find a number of biomarkers at presentation (or when measured at a 283 single time-point) increased mortality risk across both hospital cohorts (univariate ORs): 284 these included eosinopenia [24] , thrombocytopenia [25, 26] , lymphocytopenia [26, 27] and 285 increased blood urea concentration (in our case indicated by BUN) [11] . In addition, we 286 quantified the reduction in mortality risk associated with changes in these biomarkers. 287 Interestingly, we identified a number of biomarkers that have little prognostic value at 288 presentation whereas their dynamic changes do: increases in MCV and decreases in 289 MCHC post-admission, for example, increased mortality risk according the univariate 290 ORs. The external validation of the multivariate ORs for these variables indicated, 291 however, these findings were inconsistent across hospitals. These results highlight the 292 potential importance of measuring dynamic changes in biomarkers for patient prognosis 293 and the importance of external validation. Our model could better predict outcomes for 294 patients who went on to be discharged opposed to those who eventually died, indicating 295 the challenges in assessing mortality risk in hospitalised COVID-19 patients.

Our study suffered from a number of limitations. Data availability limited the 297 prognostic factors tested, and future work is therefore required to quantify the mortality 298 risk associated with dynamic changes in other prognostic factors that are known to be 299 important at presentation. These include abnormal biomarkers of inflammation, 300 myocardial injury, acute respiratory distress syndrome (ARDS) and 301 coagulopathy [25, 27] . We also did not include time-dependent changes in certain 302 chemokines and cytokines, which can also indicate disease progression [12, 28] . 303 Additionally, we did not account for the potential impact of patient treatment on 304 dynamic changes in biomarkers or on outcomes. Mechanical ventilation of patients with 305 ARDS, for example, is used to maintain certain arterial pCO 2 values, and both 306 mechanical ventilation and certain COVID-19 pharmaceutical treatments can influence 307 inflammatory markers [29, 30] . We considered patients solely hospitalised during early 308 to mid-2020 within a single region (New York), but novel variants and existing 309 immunity may alter survival [31] . Within certain settings, patient survival has improved 310 throughout the course of the pandemic [32] , and temporal recalibration of multivariate 311 regression models, which aim to quantify the OR of survival for different prognostic 312 factors, is therefore necessary to ensure survival is not under-or overestimated [33] . 313 Whilst our model performed well across the two cohorts examined, we caution 314 against its use as a dynamic prognostic model in clinical settings. In order for it to be 315 used as thus, any such model requires training and evaluation over a much larger sample 316 size across multiple settings including the full set of factors implicated with risk. The 

Prediction models for diagnosis and prognosis of COVID-19: systematic review 327

Social 329 determinants of COVID-19 incidence and outcomes: A rapid review

Factors associated with COVID-19-related death using OpenSAFELY

Socioeconomic status determines COVID-19 incidence and related mortality in 336

Higher risk of death from COVID-19 in low-income and non-white populations of 339

Patient factors and 341 temporal trends associated with COVID-19 in-hospital mortality in England: an 342 observational study using administrative data. The Lancet Respiratory Medicine

Prognosis and prognostic 345 research: validating a prognostic model

347 Systematic evaluation and external validation of 22 prognostic models among 348

hospitalised adults with COVID-19: an observational cohort study

351 Development and validation of the ISARIC 4C deterioration model for adults 352

hospitalised with COVID-19: a prospective cohort study. The Lancet Respiratory 353 Medicine

WHO Clinical Characterisation Protocol: development and validation of the 4C 357 Mortality Score

An immune-based biomarker signature is associated with mortality in COVID-19 360 patients

Longitudinal hematologic 362 and immunologic variations associated with the progression of COVID-19 patients 363 in China

dynamic clinical and biomarker data for mortality risk prediction in COVID-19: a 366 multicentre retrospective cohort study

A Dynamic 368

Bayesian Model for Identifying High-Mortality Risk in Hospitalized

Biomarkers in COVID-19: An Up-To-Date Review. 371 Frontiers in Pediatrics

The lme4 package. R package version

Modelling survival data in medical research

Prognostic models with 376 competing risks: methods and application to coronary risk prediction

A conceptual introduction to Hamiltonian Monte Carlo

381 Stan: a probabilistic programming language. Grantee Submission

Bayesian 384 data analysis

A student's guide to Bayesian statistics. Sage

The role of peripheral blood 387 eosinophil counts in COVID-19 patients

389 Clinical Characteristics and Predictors of Outcomes of Hospitalized Patients 390

With Coronavirus Disease 2019 in a Multiethnic London National Health Service 391 Trust: A Retrospective Cohort Study

Biomarkers and 393 outcomes of COVID-19 hospitalisations: systematic review and meta-analysis

Retrospective cohort study of clinical characteristics of 2199 hospitalised patients 397 with COVID-19 in New York City

A 399 dynamic COVID-19 immune signature includes associations with poor prognosis. 400

Effect of Mechanical Ventilation on Inflammatory Mediators in Patients With 403

Acute Respiratory Distress Syndrome: a Randomized Controlled Trial

An inflammatory cytokine signature predicts COVID-19 severity and 407 survival

Danon 409 L. Risk of mortality in patients infected with SARS-CoV-2 variant of concern 410 202012/1: matched cohort study

Improving Survival of 412

Critical Care Patients With Coronavirus Disease 2019 in England: A National 413

recalibration for improving prognostic model development and risk predictions in 416 settings where survival is improving over time

The authors wish to thank the study participants for agreeing to the use of their data. 423 November 12, 2021